Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company, known for its proprietary ARCUS® platform which develops in vivo gene editing therapies including gene elimination, insertion, and excision programs, will present on April 7, 2025, at 3:00 PM ET in Track 2.
A live webcast of the presentation will be available through the company's website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. The webcast recording will remain accessible for approximately 30 days after the event.
Precision BioSciences (Nasdaq: DTIL), un'azienda di editing genetico in fase clinica, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. L'azienda, nota per la sua piattaforma proprietaria ARCUS® che sviluppa terapie di editing genetico in vivo, inclusi programmi di eliminazione, inserimento ed escissione di geni, presenterà il 7 aprile 2025, alle 15:00 ET nel Tracciato 2.
Una trasmissione in diretta della presentazione sarà disponibile attraverso il sito web dell'azienda nella sezione Investitori sotto Eventi & Presentazioni su investor.precisionbiosciences.com. La registrazione della trasmissione rimarrà accessibile per circa 30 giorni dopo l'evento.
Precision BioSciences (Nasdaq: DTIL), una empresa de edición genética en etapa clínica, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Needham sobre Salud. La empresa, conocida por su plataforma propietaria ARCUS® que desarrolla terapias de edición genética in vivo, incluidos programas de eliminación, inserción y excisión de genes, presentará el 7 de abril de 2025, a las 3:00 PM ET en la Pista 2.
Una transmisión en vivo de la presentación estará disponible a través del sitio web de la empresa en la sección de Inversores bajo Eventos y Presentaciones en investor.precisionbiosciences.com. La grabación de la transmisión permanecerá accesible durante aproximadamente 30 días después del evento.
Precision BioSciences (Nasdaq: DTIL), 임상 단계 유전자 편집 회사,가 제24회 니드햄 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 독자적인 ARCUS® 플랫폼으로 알려진 이 회사는 유전자 제거, 삽입 및 절제 프로그램을 포함한 생체 내 유전자 편집 치료제를 개발하며, 2025년 4월 7일 오후 3시 ET에 트랙 2에서 발표할 예정입니다.
발표의 실시간 웹캐스트는 회사 웹사이트의 투자자 섹션에서 이벤트 및 프레젠테이션 아래에서 확인할 수 있습니다: investor.precisionbiosciences.com. 웹캐스트 녹화는 이벤트 후 약 30일 동안 접근할 수 있습니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise de modification génétique en phase clinique, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé. L'entreprise, connue pour sa plateforme propriétaire ARCUS® qui développe des thérapies de modification génétique in vivo, y compris des programmes d'élimination, d'insertion et d'excision de gènes, présentera le 7 avril 2025 à 15h00 ET dans la Piste 2.
Un webinaire en direct de la présentation sera disponible sur le site Web de l'entreprise dans la section Investisseurs sous Événements & Présentations à investor.precisionbiosciences.com. L'enregistrement du webinaire restera accessible pendant environ 30 jours après l'événement.
Precision BioSciences (Nasdaq: DTIL), ein Unternehmen für Gen-Editing in der klinischen Phase, hat seine Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz bekannt gegeben. Das Unternehmen, das für seine proprietäre ARCUS®-Plattform bekannt ist, die in vivo-Gene-Editing-Therapien entwickelt, einschließlich Gene-Eliminierung, -Einfügung und -Exzisionsprogrammen, wird am 7. April 2025 um 15:00 Uhr ET im Track 2 präsentieren.
Ein Live-Stream der Präsentation wird über die Website des Unternehmens im Bereich Investoren unter Veranstaltungen & Präsentationen auf investor.precisionbiosciences.com verfügbar sein. Die Aufzeichnung des Webcasts bleibt etwa 30 Tage nach der Veranstaltung zugänglich.
- None.
- None.
Presentation Details:
Date: Monday, April 7, 2025
Time: 3:00 PM ET in Track 2
Format: Presentation
Webcast Registration: Link
A live webcast will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will be available for approximately 30 days following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV such as in the DMD program).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401069549/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When is Precision BioSciences (DTIL) presenting at the Needham Healthcare Conference 2025?
How can investors watch Precision BioSciences' (DTIL) Needham Conference presentation?
How long will DTIL's Needham Conference presentation replay be available?
What types of gene editing programs does Precision BioSciences (DTIL) develop?
